603392 万泰生物
2026/03 - 三个月
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额(232,044)89,754355,0821,537,8234,132,593
投资活动产生之现金流量净额315,548(759,009)(1,503,359)(2,053,737)(3,513,902)
筹资活动产生之现金流量净额7,259472(612,743)(893,260)3,126,896
汇率变动对现金及现金等价物的影响(12,591)(13,270)4,3857,61926,262
现金及现金等价物净增加/(减少)78,172(682,053)(1,756,636)(1,401,554)3,771,849
期初现金及现金等价物余额1,344,9532,027,0063,783,6425,185,1961,413,347
期末现金及现金等价物余额1,423,1251,344,9532,027,0063,783,6425,185,196